Renal Cell Carcinoma

The era of immunotherapy has opened new perspectives in renal cell carcinoma (RCC), which is one of the tumors most highly infiltrated with cluster of differentiation T cells and PD-1 expression, partially accounting for its sensitivity to immunotherapy.

First-line therapy with pembrolizumab plus axitinib significantly improved overall survival (OS), progression-free survival (PFS), and objective response rates compared with standard-of-care sunitinib in patients with clear cell metastatic renal cell carcinoma (RCC) in KEYNOTE-426.